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Abstract 
 
Aldosterone is an important factor supporting placental growth and fetal development. 
Recently, expression of placental growth factor (PlGF) has been observed in response to 
aldosterone exposure in different models of atherosclerosis. Thus, we hypothesized that 
aldosterone up-regulates growth-adaptive angiogenesis in pregnancy, via increased placental 
PlGF expression. 
We followed normotensive pregnant women (n=24) throughout pregnancy and confirmed 
these results in a second independent first trimester cohort (n=36). Urinary 
tetrahydroaldosterone was measured by gas chromatography-mass spectrometry and corrected 
for creatinine. Circulating PlGF concentrations were determined by ELISA. Additionally, 
cultured cell lines, adrenocortical H295R and choriocarcinoma BeWo cells, as well as primary 
human third trimester trophoblasts were tested in vitro. PlGF serum concentrations positively 
correlated with urinary tetrahydroaldosterone corrected for creatinine in these two independent 
cohorts. This observation was not due to PlGF, which did not induce aldosterone production in 
cultured H295R cells. On the other hand, PlGF expression was specifically enhanced by 
aldosterone in the presence of forskolin (p<0.01) in trophoblasts. A pronounced stimulation of 
PlGF expression was observed with reduced glucose concentrations simulating starvation 
(p<0.001). 
In conclusion, aldosterone stimulates placental PlGF production, enhancing its availability 
during human pregnancy, a response amplified by reduced glucose supply. Given the crucial 
role of PlGF in maintaining a healthy pregnancy, these data support a key role of aldosterone 
for a healthy pregnancy outcome. 
2 
 
Introduction 
 
Evidence accumulates for almost every physiological system to be closely embedded and 
regulated by environmental conditions and factors. In pregnancy, similar to the non-pregnant 
state, the renin-angiotensin II-aldosterone system is a mechanism closely related to salt and 
water availability (1). As such, numerous effects beneficial to pregnancy have already been 
attributed to aldosterone. These include, but are not limited to maternal plasma volume 
expansion, improved fetal conditions and size, placental growth and lower maternal blood 
pressure (2-8). We recently described that vascular endothelial growth factor (VEGF) alone 
and in combination with angiotensin II, directs augmented aldosterone production in 
pregnancy (9), suggesting a physiological survival benefit.  
 
These advantageous characteristics of aldosterone are in marked contrast to its deleterious 
effects in the non-pregnant state. Organ fibrosis and atherosclerosis are promoted by excess 
aldosterone (10). Upon exposure of vessels to aldosterone in models of atherosclerosis, 
enhanced placental growth factor (PlGF) expression has been observed, mediated by a 
mineralocorticoid responsive element in the promoter region of plgf (10, 11). In non-pregnant 
systemic vasculature, aldosterone-dependent PlGF expression leads to vascular injury, 
atherosclerosis, plaque formation and its inflammatory response (10, 11). 
PlGF is considered to be crucial in pregnancy to initiate and perpetuate placental angiogenesis 
(reviewed in Zygmunt et al. Eur J Obstet Gynecol Reprod Biol 2003). As low levels 
compromise placental development, it also serves as early marker of pregnancies complicated 
by pre-eclampsia, a disease of placental origin (12, 13). 
The role of environmental conditions on PlGF expression in pregnancy is less clear. 
Upregulation of angiogenic factors, such as PlGF, in trophoblast seems not to be supported by 
hypoxia and hypoxia-induced factor-1α (14). As such, other regulatory pathways must be 
considered such as glucose availability, which might play a role in this process. While 
maternal serum levels of PlGF are high in diabetic pregnancies, similar to certain vascular 
beds such as in the retina, experimental evidence in diabetic rats suggests low PlGF levels in 
the placenta; thereby a differential regulation between systemic and placental PlGF in 
response to altered glucose availability (15-17). 
 
Given the high systemic availability of aldosterone during pregnancy (7, 18), we hypothesized 
that aldosterone up-regulates growth-adaptive angiogenesis via placental PlGF expression. 
More specifically, we first aimed to identify trophoblast-derived aldosterone-sensitive PlGF 
expression; second to explore conditions most likely related to increased responsiveness such 
as starvation; and third, to investigate the relationship between aldosterone and PlGF in human 
pregnancy. 
3 
 
Methods 
 
Patients 
 
A set of healthy pregnant women selected from the Bernese pregnancy registry at the 
Department of Obstetrics and Gynecology, University Hospital of Bern, with a complete 
scheduled sampling of serum and urine were included in the study. Clinical data were 
prospectively collected including obstetric parameters, ultrasound data, standardized 
measurement of office blood pressure and pregnancy outcome. Only normotensive, healthy 
pregnant women were included in the analysis. Visits were at gestation week 11±2, 20±2, 
28±2 and at birth. The study was approved by the ethics committee of the Canton of Bern and 
adheres to the principles of the Declaration of Helsinki. Study subjects were only included in 
the study after obtaining written informed consent. 
  
A confirmatory patient set (n=36) was derived from a prospective pregnancy cohort (number 
initially screened n=3918) at Maternity Units in Glasgow, UK. First trimester samples were 
taken at booking and those investigated who maintained normotensive throughout their 
pregnancy. The study was also approved by the West of Scotland Research ethics Committee 
and adheres to the principles of the Declaration of Helsinki. Study subjects were only included 
in the study after signing informed consent.  
 
Material and cell lines 
 
Collagen I-coated cell culture plates used for cell experiments were from Becton Dickinson 
(Basel, Switzerland). Cell culture media, L-glutamine, penicillin/streptomycin and HEPES 
were from Life Technologies, Inc./Invitrogen (Basel, Switzerland). Aldosterone was from 
Steraloids, Inc. (Brunschwig, Basel, Switzerland), forskolin, spironolactone, PlGF and fetal 
bovine serum (FBS) from Sigma (Buchs SG, Switzerland). Penicillin, streptomycin, and 
amphotericin B used for primary cell cultures were obtained from Invitrogen (Basel, 
Switzerland).  
 
The human choriocarcinoma cell line BeWo and the adrenocortical carcinoma cell line NCl-
H295R (H295R) were obtained from American Type Culture Collection (Manassas, VA). 
Human primary term trophoblasts were isolated from term placentas (38 - 40 w) of healthy 
donors after obtaining informed consent from pregnant women at the Department of Obstetrics 
and Gynecology, University Hospital Bern, Switzerland. The isolation procedure was 
previously described (19). Primary cytotrophoblasts were resuspended in DMEM/F12K (1:1) 
containing 10% FBS, penicillin, streptomycin, and amphotericin B and plated on collagen I-
coated culture dishes. Cells were cultured at 37°C and 5 % CO2. 
 
The human adrenal cell line H295R was cultured in DMEM-F12, 0.1 % ITS+, and 5 % NU-I. 
For the experiments, H295R cells were than incubated for 24 h in serum-free DMEM-F12 
containing PBS, angiotensin II, PlGF or the combination of angiotensin II and PlGF. RNA 
was then extracted. 
 
Human primary term trophoblasts and BeWo cells were cultured for 24 h in DMEM:F12K 
(1:1) medium with 10 % FBS, then cells were washed with PBS, and fresh medium containing 
either 10% (for primary trophoblasts) or 0.1 % (for BeWo) FBS supplemented with Aldo, 
forskolin or spironolactone for 6 or 24 h. Following this incubation time, RNA was extracted 
from the cells and supernatant was taken for PlGF protein measurements. 
 
Real-time PCR 
 
Total RNA was extracted using Trizol reagent (Invitrogen, Basel, Switzerland). The RNA was 
then reverse transcribed (Prom II RT, Promega). For the real-time PCR, primers and probes 
for PlGF were obtained from Applied Biosystems (PlGF, Hs00182176_m1; CYP11B2, 
4 
 
Hs01597732_m1; Applied Biosystems, Foster City, CA). GAPDH and cyclophilin A primers 
and probes (Applied Biosystems) served as independent endogenous controls. Real-time PCR 
reactions were performed using the Universal ProbeLibrary Assay probes and Taqman Fast 
Universal PCR Master Mix (Invitrogen, Basel, Switzerland). All data were normalised to 
cyclopholin A or GAPDH and presented as fold-change compared to the mean of the controls. 
 
PlGF ELISA 
 
BeWo and human primary term trophoblasts conditioned media were taken for PlGF protein 
measurement using a commercially available quantitative sandwich enzyme-linked 
immunosorbent assays (ELISA, R&D Systems Europe Ltd., Abingdon, UK).  
 
Collection of urine and serum/plasma 
 
Morning urine samples were obtained from pregnant women in the longitudinal Bernese study 
and in the first trimester from the Glasgow cohort as has been described for population-based 
assessments (20). In all urine collections, creatinine concentrations were determined using 
routine methods. Serum and urine aliquots were stored at -80°C until further analysis. 
 
Gas chromatography-mass spectrometry (GC-MS) 
 
Urinary tetrahydro-aldosterone (TH-aldosterone) was analyzed by GC-MS according to the 
method originally described by Shackleton and applied by us as reported earlier (7, 21). 
Briefly, urine preparation consisted of pre-extraction, enzymatic hydrolysis, extraction from 
the hydrolysis mixture, derivatization, and gel filtration. Medroxyprogesterone (2.5 g) was 
added as recovery standard to 1.5 ml urine. Samples were extracted on a Sep Pak C18 column, 
dried, reconstituted in 0.1 M acetate buffer (pH 4.6) and hydrolyzed with powdered Helix 
pomatia enzyme (12.5 mg) and 12.5 l of -glucuronidase/arylsulfatase liquid enzyme at 55°C 
for 3 h. The resulting free steroids were extracted on a Sep Pak C18 cartridge and 0.15 µg of 
3β5β-TH-aldosterone was added as a standard for derivatization and chromatography. The 
samples were derivatized to form methyloxime-trimethylsilyl ethers. The derivatives were 
purified by gel filtration on Lipidex 5000 columns. 
 
Samples were analyzed on a gas chromatograph 6890N equipped with a mass selective 
detector 5973N (Agilent, La Jolla CA, USA) during a temperature-controlled run over 35 min 
by selected ion monitoring. One specific ion was monitored for each compound analyzed. A 
known amount of 3α5β-TH-aldosterone was measured on a regular basis to act as a calibration 
standard. The recovery of the analysis was checked with medroxyprogesterone and results 
were corrected for the loss during sample preparation. The urinary concentration of 3α5β-TH-
aldosterone was normalized to urinary creatinine concentration. 
 
Statistical analysis  
 
All data in figures are presented as mean  SEM, whereas in text and tables mean ± SD or 
mean [95% CI] are indicated. Data were tested for standard normal distribution using the 
Kolmogorov–Smirnov test before applying either unpaired student’s t-test or nonparametric 
testing accordingly to analyze the difference observed between two groups. After testing for 
normal distribution, Pearson’s correlation tests were used to correlate urinary TH-aldosterone 
concentrations to serum PlGF. Significance was assigned at p<0.05. All statistical analyses 
were performed using GraphPad PRISM version 6 (PRISM,USA). 
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Results 
 
Clinical data 
 
Demographic data of both the longitudinal Bernese and the complementary first trimester 
Glasgow cohort of healthy pregnant women with uneventful pregnancies and outcomes are 
shown in Table 1. The Glasgow cohort, though younger, is characterized by a higher risk 
profile including a higher BMI and blood pressure and characterized by earlier birth with 
lower birth weights. 
 
Association between urinary TH-aldosterone and serum PlGF levels 
 
Serum levels of PlGF rose, as expected, along gestation. In normotensive pregnancies, we 
identified a positive relationship between urinary TH-Aldo/creatinine levels and serum PlGF 
irrespective of gestational age (Figure 1A, r=0.3259, R2=0.1062; p=0.001). This strong 
correlation is maintained irrespective of limiting the analysis up to week 28 only, thus 
excluding birth data (r=0.2951, r2=0.0871, p=0.0107). We further tested this association in 
normal pregnancy in a second cohort of first trimester pregnancy samples (Glasgow cohort) 
and the relationship was confirmed (r=0.3581, R2=0.1282, p=0.0295). Within pregnancy salt 
intake, which could potentially affect tetrahydroaldosterone excretion, as assessed by urinary 
Na+ excretion was stable (Figure 1B). The expected rise in tetrahydroaldosterone excretion 
along gestation could be observed (Figure 1C; p<0.01).  
 
Does PlGF stimulate adrenal aldosterone production? 
 
Upon stimulation of the human corticoadrenal carcinoma cell line H295R with PlGF (100 
ng/ml), no augmentation of aldosterone synthase mRNA expression was observed, whereas 
angiotensin II (10-7 M) markedly amplified transcript availability (Figure 2, p<0.0001). Co-
incubation of PlGF and angiotensin II did not further raise aldosterone synthase expression, 
compared to angiotensin II alone (Figure 2). 
 
Aldosterone-dependent PlGF expression in human trophoblasts 
 
Incubation of the human trophoblast cell line, BeWo with different concentrations of 
aldosterone (10-11 to 10-7 M) did not increase PlGF expression. Upon challenging BeWo cells 
by adding forskolin (2 x 10-6 M) to stimulate Protein Kinase A (PKA) and to induce 
syncytialization, we observed raised PlGF transcription (p<0.0001 vs. control). Likewise, 
time-course experiments indicated a maximal stimulation by aldosterone already after 6 h, an 
incubation period which was used in consecutive experiments. Upon co-incubation with 
forskolin for a time period of 6 h, aldosterone enhanced PlGF expression with increasing 
effectiveness towards lower concentrations (10-7 to 10-11 M, ANOVA p=0.0011; Figure 3A). 
Prolonged pre-incubation with forskolin for 48 h to induce syncytialization of BeWo cells 
reversed the dose relationship with aldosterone (10-7 to 10-11 M, p=0.0006 [for aldosterone 10-7 
M] and p=0.0012 [for aldosterone 10-9 M] vs. forskolin), added during the last 6 h (Figure 3B). 
 
When spironolactone (10-6 M) was added to cultured human primary third trimester 
trophoblasts for 24 h, a slight but consistent reduction of PlGF production was observed 
(p=0.026; Figure 3C), either unspecific or due to inhibiting the effect of mineralocorticoid 
active steroid hormones present in trophoblasts. Upon analysis of the baseline steroid hormone 
expression in trophoblasts, we could identify within the cells and in the supernatant a pattern 
compatible with intrinsic stimulatory mineralocorticoid-active steroid hormones, including the 
cortisol precursor 11-deoxycortisol and cortisol metabolites, but not corticosterone metabolites 
or aldosterone (Table 2). These findings were verified in cells cultured in the presence of 
charcoal-treated medium eliminating preformed steroid hormones. 
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Addition of aldosterone (10-7 M) further (p=0.0175) enhanced forskolin-induced (2 x 10-6 M, 
p=0.025) PlGF transcription, which could be completely reversed by the addition of 
spironolactone (p=0.024; Figure 3C). The PlGF protein expression as measured in primary 
human trophoblasts paralleled these observations (data not shown). 
A mild but consistent inhibitory impact of incubation with cortisol on PlGF production 
suggested no unspecific stimulation of the mineralocorticoid receptor by cortisol in conditions 
of unaffected 11β-hydroxysteroid dehydrogenase activity type 2, an entity reported earlier by 
our group and others (data not shown) (22, 23). 
 
PlGF expression simulated by low glucose incubation 
 
To study whether insufficient nutrient availability triggers or enhances angiogenic signals such 
as PlGF, we exposed BeWo cells to low glucose concentrations (3.5 vs. 16 mmol/l). In these 
cells, the forskolin-stimulated increase in PlGF expression (p=0.0035 vs. control; Figure 4) 
disclosed in our baseline glucose concentration, was further enhanced in low glucose 
conditions (p<0.0001 vs. normal glucose). Incubation with aldosterone (10-7 M) alone did not 
affect PlGF expression, irrespective of the glucose concentration. Upon co-incubation of 
forskolin (2 x 10-6 M) and aldosterone we observed a 3-fold stimulation of PlGF expression in 
normal (p=0.0319) and a more than 10-fold enhanced expression in low glucose 
concentrations (p<0.0001). Accordingly, co-incubation of both aldosterone and forskolin in 
low glucose conditions was strikingly more intense then in normal glucose conditions 
(p<0.0001; Figure 4). 
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Discussion 
 
Limited data in clinical conditions outside pregnancy suggest a role for aldosterone in up-
regulating PlGF. PlGF is a clinical useful marker of placental angiogenic properties in 
pregnancy. Given the placental growth properties of aldosterone in pregnancy, such a feature 
might be of importance for adaptive angiogenesis. 
 
This study demonstrates that in normal human pregnancy, circulating PlGF levels are closely 
linked to aldosterone availability throughout pregnancy. Obviously, the aldosterone-dependent 
PlGF stimulation is not challenged in the first trimester in pregnancy. Earlier studies suggest 
an insufficient aldosterone response in the high aldosterone pregnancy state, either genetically 
or due to modifying factors (3, 9). 
 
Given the known stimulatory effect of angiotensin II and the angiogenic VEGF on adrenal 
aldosterone production (9), the VEGF homologue PlGF is also a likely candidate. Conversely, 
VEGF-receptor type 1, the target of PlGF is not expressed on adrenal epithelial cells, 
suggesting the absence of any PlGF effect. As expected, PlGF did not stimulate aldosterone 
production in vitro in adrenal cells, known to produce aldosterone via CYP11B2, whereas on 
the contrary, we could clearly show that given certain prerequisites, aldosterone stimulates 
PlGF expression. PKA activation, as stimulated by the addition of forskolin and supporting 
syncytialization was critically required. Addition of aldosterone enhanced PlGF expression, 
which was further amplified in conditions of low glucose, simulating starvation. These 
observations are in agreement with the assumption of an enhanced angiogenesis upon starving 
trophoblasts. Moreover, they bridge environmental conditions and local regulation to an 
overall placental response. 
 
Additionally, our findings are in line with observations in animal models of atherosclerosis 
and vascular damage, where aldosterone increased aortic PlGF expression, but also in non-
aged mouse aorta (10, 11, 24). While the former two models suggest a strong PlGF stimulation 
upon aldosterone in conditions of local oxidative stress and compromised blood supply, the 
latter also identified aldosterone-stimulated PlGF expression in non-compromised vessels. 
 
The systemic response in humans to diabetic conditions, suggests an enhanced PlGF 
production, which has been observed in certain microvascular areas. However, PlGF 
production is reduced within the placenta in experimental hyperglycemic rats (15-17). In 
contrast, low glucose or fasting conditions are known to induce hepatic gluconeogenesis in a 
cAMP/PKA/CREB-dependent manner (25). This pathway has been shown to activate the 
PlGF gene promoter explaining the response observed with low glucose concentrations in our 
experiments (26). 
 
The results from the current study could explain an effective coordinated action of aldosterone 
on placental growth and adaptive angiogenesis. Nevertheless, we cannot extrapolate from our 
data whether the PlGF systemically found during pregnancy is purely of placental origin, 
given the huge endothelial and vascular smooth muscle cell mass in the systemic maternal 
circulation. Very carefully obtained data from placental vessels have suggested a major 
placental source of PlGF, as the placental PlGF arterial inflow was low, whereas the outflow 
was high (27). This report does not preclude a local vascular PlGF production, potentially 
providing significant cellular auto- or paracrine humeral adaptations. 
 
The strength of our current investigation is the combination of independent clinical cohorts 
with additional isolated primary term human trophoblast cell culture in vitro. In addition, 
application of different cell culture systems, beyond the rather artificial model, given by the 
choriocarcinoma BeWo cell lines, by use of carefully isolated and thoroughly characterized 
primary term human trophoblasts adds further merit (28). A few limitations exist; first, 
although placental growth is significant in the second trimester, isolated human primary 
trophoblasts were not available within this time frame without further comorbid conditions 
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precluding their use. Second, systemic PlGF is only a surrogate of the actual placental 
production of PlGF, though obviously closely related to urinary aldosterone. 
 
In conclusion, we have demonstrated that by stimulating placental PlGF production, 
aldosterone has additional effects in pregnancy beyond trophoblast growth promotion and 
optimizing fetal hemodynamics. The close relationship with conditions of starvation, suggests 
that this could be a local trigger occurring upon aldosterone-stimulated trophoblast 
proliferation in less well vascularized areas, as summarized and depicted in Figure 5. An 
impact of alternative mineralocorticoid active steroid hormones is likely, yet not major.  
 
Cortisol has a minor inhibitory function in this process, which might be overwhelming in 
conditions of established pre-eclampsia, with compromised intracellular cortisol degradation 
by the enzyme 11-hydroxysteroid dehydrogenase type 2, as has been previously reported (29, 
30). Inappropriate aldosterone availability could thus be of clinical interest and 
supplementation by artificial mineralocorticoid agonistic drugs, such as fludrocortisone might 
enhance PlGF in conditions of critically low availability. Further studies are definitely 
warranted to further explore these issues. 
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Figure legends 
 
Figure 1 
 
A) Association between urinary tetrahydroaldosterone concentration corrected for creatinine 
and serum placental growth factor (PlGF) levels in healthy pregnancy across gestation (first 
cohort). A positive correlation was observed (r=0.2951, R2=0.0871; p=0.0107; n=24 
individual women). 
B) Salt intake indicated as urinary Na+/creatinine remained stable throughout the indicated 
gestational ages (n=24 individual women). 
C) The gestational rise in aldosterone availability was assessed as urinary 
tetrahydroaldosterone excretion corrected for urinary creatinine (n=24 individual women); 
**p<0.01.  
 
Figure 2 
 
Aldosterone synthase (CYP11B2) expression, following incubation with angiotensin II (Ang 
II) and/or placental growth factor (PlGF). PlGF does not stimulate adrenal CYP11B2 
expression. Upon stimulation of the human corticoadrenal cell line H295R with PlGF (100 
ng/ml) and with Ang II (10-7 M) alone, or in combination for 24 h, PlGF did not contribute to a 
stimulated CYP11B2 transcript expression as measured by TaqMan PCR corrected for 
cyclophilin A. Mean ± SEM is given (n=3); ***p<0.0001. 
 
Figure 3 
 
Aldosterone-dependent augmentation of forskolin-induced PlGF transcription in the BeWo 
cell line and cultured primary third trimester human trophoblasts.  
A) Short time exposure with forskolin (2 x 10-6 M) for 6 h sensitized cultured BeWo cells to 
enhanced PlGF transcription in the simultaneous presence of minor concentrations of 
aldosterone. Depicted is a representative experiment (mean ± SEM, n=3); **p=0.0011 
ANOVA of forskolin-treated experiments. 
B) If the pre-exposure of cultured BeWo cells to forskolin was extended to 48 h, higher 
concentrations of aldosterone for 6 h were required for the PlGF augmentation. Mean ± SEM, 
n=3); ***p<0.001. 
C) In cultured human primary trophoblasts 24 h incubation with spironolactone (10-6 M) 
slightly but consistently reduced PlGF expression. Addition of aldosterone (10-7 M) further 
enhanced forskolin-induced (2 x 10-6 M) PlGF transcription, which could be completely 
reversed by the addition of spironolactone. Mean ± SEM are given (n=3-6); *p<0.05. 
 
Figure 4 
 
Effect of starvation on the BeWo cell line, simulated by low glucose exposure in the 
incubation medium on PlGF expression. In normal glucose conditions (black bars) forskolin (2 
x 10-6 M) stimulated PlGF expression further enhanced by aldosterone (10-7 M). Reducing 
glucose availability (white bars) led to a marked increase in PlGF transcription irrespective of 
incubation with forskolin alone or if forskolin was combined with aldosterone. Mean ± SEM 
are given, n=4-10; *p<0.05, **p<0.01, ***p<0.001. 
 
Figure 5 
 
Scheme indicating the proposed regulation of placental angiogenic adaptation in normal and 
environmental challenging conditions, favoring high aldosterone levels and leading to 
starvation. This will contribute to local starvation due to increased proliferation and 
insufficient angiogenesis. The presence of PKA activation and aldosterone, enhance PlGF 
production and thus support angiogenesis. Similarly, systemic starvation and reduced maternal 
access to salt and water will in turn drive aldosterone synthesis, subsequently accentuating 
12 
 
PlGF expression. High local PlGF levels will then support placental angiogenesis and 
systemic maternal endothelial adaptation and an appropriate pregnancy outcome.  
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Table 1 
 
Details of primiparous pregnant women; data show as mean ± SD. 
 
Main demographic data Berne cohort Glasgow cohort p 
Patients [n]   26       36      
Age [y]   31.5 ±   0.8   29.5 ±   1.0 <0.0001 
Gestational age at birth [w]   39.8 ±   0.3   39.3 ±   0.6 0.0002 
Neonatal weight [g] 3481   ± 110 3345   ± 145 0.0002 
Office blood pressure at booking  
   systolic [mmHg]  113   ±   2  115   ±   2 0.0003 
   diastolic [mmHg]   67   ±   1   70   ±   2 <0.0001 
BMI before pregnancy [kg/m2]   21.4 ±   0.7   27.2 ±   1.0 <0.0001 
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Table 2 
 
Steroid hormone metabolites in cultured BeWo cells 
 
Steroid hormone metabolites Expressed in BeWo cells cultured in 
Regular medium Charcoal-treated 
medium 
 0 h 24 h 0 h 24 h 
Androgens 
Androsterone x x x x 
Etiocholanolone x x x x 
Androstenediol     
11-Oxo-Etiocholanolon     
11β-Hydroxyandrosterone x x x x 
11β-Hydroxyetiocholanolone x x x x 
Dehydroepiandrosterone  x  x 
5-Androstene-3β,17β-diol     
16α-Hydroxy-DHEA  x  x 
5-Androstene-3β,16α,17β-triol     
5-Pregnene-3β, 16α,17β-triol x x x x 
Testosterone     
5α-Dihydrotestosterone     
Estrogens 
Estriol x x x x 
17β-Estradiol x x x x 
Progesterons 
17-Hydroxypregnanolon     
Pregnanediol     
Pregnanetriol x x x x 
11-Oxopregnanetriol x x x x 
11-Deoxycortisol 
Tetrahydro-11-deoxycortisol x x x x 
Aldosterone 
Tetrahydroaldosterone     
Corticosterones 
Deoxycorticosterone     
Tetrahydrodeoxycorticosterone     
Tetrahydrodihydrocorticosterone     
Tetrahydrocorticosterone     
5α-Tetrahydrocorticosterone     
18-OH-tetrahydrodihydrocorticosterone     
Cortisols 
Cortisone     
Tetrahydrocortisone x x x x 
α/β-Cortolone x x x x 
20α/β-Dihydrocortison     
Cortisol     
Tetrahydrocortisol x x x x 
5α-Tetrahydrocortisol x x x x 
α-Cortol     
β-Cortol x x x x 
20α/β-Dihydrocortisol     
6β/18-Hydroxycortisol     
 
